Clinical Scorecard: Systematic Review of Urinary Biomarkers for the Detection of Renal Cell Carcinoma
At a Glance
Category
Detail
Condition
Renal Cell Carcinoma (RCC)
Key Mechanisms
Detection of urinary biomarkers indicating presence of RCC, including DNA methylation and other molecular markers
Target Population
Adults with sporadic RCC
Care Setting
Diagnostic evaluation prior to surgical intervention, outpatient or clinical laboratory settings
Key Highlights
RCC is the 14th most frequently diagnosed cancer worldwide, with a mean diagnosis age of 75 years.
Approximately 20–30% of small renal masses detected by imaging are benign, leading to potentially avoidable nephrectomies.
Urinary biomarkers with diagnostic properties (sensitivity, specificity, AUC) are being investigated to improve non-invasive early detection of RCC.
Guideline-Based Recommendations
Diagnosis
Use imaging techniques (CT, ultrasound, MRI) for initial detection of renal lesions.
Consider urinary biomarker assays as adjunctive tools to differentiate benign from malignant renal masses, especially for small renal masses (≤ 4 cm).
Focus on biomarkers with an area under the curve (AUC) ≥ 0.80 for promising diagnostic utility.
Management
Avoid unnecessary nephrectomies by improving preoperative diagnostic accuracy using urinary biomarkers.
Incorporate non-invasive urine-based assays to reduce patient burden.
Monitoring & Follow-up
Monitor biomarker performance and validation through standardized protocols and head-to-head comparisons.
Assess biomarker diagnostic accuracy continuously to support clinical translation.
Risks
Be aware of selection bias and variability in laboratory techniques affecting biomarker reliability.
Recognize that current biomarkers are not yet validated for routine clinical use.
Patient & Prescribing Data
Adults with suspected sporadic renal cell carcinoma undergoing diagnostic evaluation
Urinary biomarkers are under investigation to guide clinical decision-making and potentially reduce unnecessary surgical interventions; however, none are currently implemented in routine clinical practice.
Clinical Best Practices
Follow PRISMA guidelines for systematic review and evidence synthesis in biomarker research.
Use standardized quality assessment tools such as the adapted STROBE checklist to evaluate study bias and validity.
Prioritize biomarkers with high diagnostic accuracy (AUC ≥ 0.80) for further validation and clinical translation.
Incorporate multidisciplinary approaches combining imaging and biomarker data to improve diagnostic precision.
by Jaycey F. Kelly, Iryna V. Samarska, Bram Ramaekers, Tom Marcelissen, Joep G. van Roermund, Maureen J. B. Aarts, Thomas Kerkhofs, Tom Hermans, Frits van Osch, Tim de Meyer, Leo J. Schouten, Kim M. Smits
